GLP-1 Drugs and Depression: What the FDA and the Studies Found
The FDA requested removal of the suicide warning from three GLP-1 labels. What the agency found, what a Nordic cohort showed, and what remains uncertain.
On this page
In January 2026, the FDA requested that Wegovy, Zepbound and Saxenda remove warnings about suicidal thoughts or behavior after its review found no increased risk with GLP-1 medicines3. Zepbound’s prescribing information records removal of the warning in February 20264. Our broader guide to GLP-1 side effects covers the risks that remain on the label.
Where the concern started
Regulatory monitoring for a drug side effect usually starts with signal detection — patterns in spontaneous adverse-event reports, not proof of causation. A 2024 pharmacovigilance analysis of the EudraVigilance database, which collects individual case safety reports submitted across the EU, examined psychiatric adverse events reported alongside semaglutide, liraglutide and tirzepatide use1. This is exactly the kind of data that raises a regulatory flag: real reports exist, submitted by clinicians and patients, and they're worth taking seriously enough to investigate formally. What this kind of database cannot do is establish whether the drug caused the event, since there's no comparison group of similar patients who weren't taking the drug — a limitation the researchers running formal cohort studies were specifically trying to address.
What a large Nordic cohort found
In 2024, researchers used nationwide prescription and cause-of-death registries from Sweden and Denmark to directly compare suicide risk between new users of GLP-1 receptor agonists and new users of a different diabetes drug class (SGLT2 inhibitors) as an active comparator — a design built specifically to control for the fact that people starting either drug class share similar underlying health conditions2. The study followed 124,517 GLP-1 users and 174,036 SGLT2 inhibitor users for a mean of 2.5 years. The results were reassuring: 77 suicide deaths occurred among GLP-1 users versus 71 among SGLT2 inhibitor users — a hazard ratio of 1.25, with a confidence interval (0.83–1.88) that included no effect. For the composite of suicide death and nonfatal self-harm, the hazard ratio was actually lower on GLP-1 drugs, at 0.83. For incident depression and anxiety diagnoses specifically, the hazard ratio was 1.01 — essentially no difference at all. The researchers' own conclusion: this cohort study does not show an association between GLP-1 receptor agonist use and increased risk of suicide death, self-harm, or new depression or anxiety diagnoses.
What the FDA found
The FDA analyzed 91 placebo-controlled trials with 107,910 participants. It found no increased risk of suicidal thoughts or behavior or of psychiatric events such as anxiety or depression. The agency also reviewed a separate observational study from its Sentinel system and found no increased risk of intentional self-harm in the comparison it examined3. These results address a population-level signal. They cannot determine what caused an individual person’s symptoms.
What this means in practice
Discuss your mental-health history and any new or worsening symptoms with your prescriber. The change in labeling does not make a serious symptom less important. If you think you may act on thoughts of harming yourself, seek emergency help immediately. For how the two medications were studied and what the results can tell an individual patient, see our semaglutide and tirzepatide evidence comparison.
Frequently asked questions
Do GLP-1 drugs cause depression?
The FDA’s analysis of 91 placebo-controlled trials found no increased risk of depression or anxiety. A separate Nordic cohort comparing GLP-1 users with users of another diabetes drug class also found no evidence of an increase in new depression or anxiety diagnoses.
Does Zepbound still carry the suicidal thoughts and behavior warning?
No. The FDA requested removal in January 2026 after finding no increased risk in its review. Zepbound’s prescribing information records the removal in February 2026.
Do GLP-1 drugs increase suicide risk?
The FDA found no increased risk of suicidal thoughts or behavior in its analysis. A 2024 study of 124,517 GLP-1 users found a hazard ratio of 1.25 for suicide death versus a comparator drug class, with a confidence interval that included no effect, and a hazard ratio of 0.83 (lower risk) for the composite of suicide death and nonfatal self-harm.
Should I still tell my provider if I notice mood changes on a GLP-1 drug?
Yes. Tell your prescriber about new or worsening mood symptoms. Seek emergency help immediately if you think you may act on thoughts of harming yourself.
Sources and further reading
- Tobaiqy M, Elkout H (2024). Psychiatric Adverse Events Associated with Semaglutide, Liraglutide and Tirzepatide: A Pharmacovigilance Analysis of Individual Case Safety Reports Submitted to the EudraVigilance Database. International Journal of Clinical Pharmacy. https://pubmed.ncbi.nlm.nih.gov/38265519/
- Ueda P, Söderling J, Wintzell V, et al. (2024). GLP-1 Receptor Agonist Use and Risk of Suicide Death. JAMA Internal Medicine. https://pubmed.ncbi.nlm.nih.gov/39226030/
- U.S. Food and Drug Administration (2026). FDA Requests Removal of Suicidal Behavior and Ideation Warning from GLP-1 RA Medications. FDA Drug Safety Communication. https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp
- Eli Lilly and Company (2026). Zepbound (tirzepatide) injection — Prescribing Information. Eli Lilly prescribing information. https://pi.lilly.com/us/zepbound-uspi.pdf
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.
Continue reading
GLP-1 and Alcohol: What Happens When You Drink on Semaglutide or Tirzepatide
What Wegovy and Zepbound labels say about alcohol, what randomized semaglutide trials found in alcohol use disorder, and where evidence is still limited.
ReadGLP-1 Drugs for PCOS: What the Trials Actually Show
No GLP-1 drug is FDA-approved for PCOS. What the randomized trials that exist found on weight, hormones, and reproductive outcomes — and their real limits.
ReadDoes GLP-1 Weight Loss Plateau? What the Physiology Shows
Weight loss on Wegovy or Zepbound levels off, and that's not the drug failing. What a 2024 modeling study found about why, versus diet and surgery.
ReadGLP-1 and Muscle Loss: What the Body-Composition Data Shows
GLP-1 weight loss isn't all fat. What DXA-scan substudies measured, why the lean-mass share varies so much between studies, and what it does and doesn't mean.
ReadGLP-1 Drugs Before Surgery: What the Aspiration-Risk Evidence Shows
GLP-1 drugs delay gastric emptying, raising aspiration risk under anesthesia. The actual gastric-ultrasound study data, and what it means for a procedure.
ReadGLP-1 Side Effects: What the Trials and FDA Labels Actually Show
Real numbers from the pivotal trials and FDA labels — how common nausea and diarrhea are, the boxed warnings, and when a side effect means call your provider.
Read